Prosecution Insights
Last updated: April 18, 2026
Application No. 17/610,702

CYCLIC FORMYL AND CYCLIC KETONE COMPOUNDS, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE

Final Rejection §102
Filed
Nov 12, 2021
Examiner
WELLS, LAUREN QUINLAN
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Nanjing Tech University
OA Round
4 (Final)
43%
Grant Probability
Moderate
5-6
OA Rounds
2y 11m
To Grant
99%
With Interview

Examiner Intelligence

Grants 43% of resolved cases
43%
Career Allow Rate
92 granted / 213 resolved
-16.8% vs TC avg
Strong +58% interview lift
Without
With
+57.8%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
79 currently pending
Career history
292
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
34.4%
-5.6% vs TC avg
§102
14.7%
-25.3% vs TC avg
§112
27.2%
-12.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 213 resolved cases

Office Action

§102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION This Office Action is in response to Applicant’s Arguments and Amendment filed, 02/04/2026, wherein the Amendment cancelled claims 1, 3-7, and 9-12 and added claims 13-16. Claims 13-16 are pending. Priority This application claims the following priority: PNG media_image1.png 94 652 media_image1.png Greyscale Election/Restrictions Applicant’s election without traverse of Group I, the compound and compositions thereof, and the species PNG media_image2.png 68 118 media_image2.png Greyscale of formula (I), in the reply filed on 10/24/2024, is acknowledged. The elected species is allowable over the prior art. In the instant amendment to the claims, dated 02/04/2026, species ZKD-2-1; ZKD-17; ZBM-11; ZBM-29, and ZBM-30, were deleted. As such, the examination of the Markush claim has been extended. As detailed in the following prior art rejections, the generic claim encompassing the elected species was not found patentable. Therefore, the provisional election of species is given effect, the examination is restricted to the elected species only, and claims not reading on the elected species are held withdrawn. MPEP 803.02; Ex parte Ohsaka, 2 USPQ2d 1460, 1461 (Bd. Pat. App. lnt. 1987). Should applicant, in response to this rejection of the Markush-type claim, overcome the rejection through amendment, the amended Markush-type claim will be reexamined to the extent necessary to determine patentability of the Markush-type claim. See MPEP 803.02. Claims 15-16 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention and subject matter, there being no allowable generic or linking claim. Claims 13-14 are examined on the merits herein. REJECTIONS WITHDRAWN The status for each rejection and/or objection in the previous Office Action is set out below. Claim Objections Applicant’s amendments to the claims that provide clear structural depictions, are sufficient to overcome this objection. 35 U.S.C. § 102 Applicant’s deletion of species relied upon in the previous prior art rejections, is sufficient to overcome these rejections. 35 U.S.C. § 103 Applicant’s deletion of species relied upon in the previous prior art rejection, is sufficient to overcome this rejection. REJECTIONS-MAINTAINED & NEW Applicant has deleted the previously searched species. As such, the newly applied prior art rejections are proper. Note: In the 102 rejection over STN Registry File 1837753-97-5 a typo was made in referencing PNG media_image3.png 126 292 media_image3.png Greyscale as ZBM-11; this compound is instant ZBM-5. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. (Maintained) Claim 13 is rejected under 35 U.S.C. 102(a)(1) as being anticipated by STN Registry File 1837753-97-5 (published 2015, PTO-892). STN Registry file teaches: PNG media_image3.png 126 292 media_image3.png Greyscale (pg. 2), which is instant ZBM-5. Registry number 1837753-97-5 is available as prior art as of 12/27/2015, the date it was indexed into the CAplus database. Since this date represents the date that the compound entered the CAPlus database on STN, this represents the date that each compound was made accessible to the public. Per MPEP 2128, an electronic publication, including an online database or Internet publication (e.g., discussion group, forum, digital video, or social media post), is considered to be a "printed publication" within the meaning of 35 U.S.C. 102(a)(1) and pre-AIA 35 U.S.C. 102(a) and (b) provided the publication was accessible to persons concerned with the art to which the document relates. See In re Wyer, 655 F.2d 221, 227, 210 USPQ 790, 795 (CCPA 1981). . . Electronic publications on the internet or on an online database are considered to be publicly available as of the date the item was publicly posted.” (New) Claim 13 is rejected under 35 U.S.C. 102(a)(1) as being anticipated by STN Registry File 1580971-85-2 (published 2014, PTO-892). STN Registry file teaches: PNG media_image4.png 123 312 media_image4.png Greyscale (pg. 2), which is instant ZSD-54. Registry number 1580971-85-2 is available as prior art as of 04/07/2014, the date it was indexed into the CAplus database. Since this date represents the date that the compound entered the CAPlus database on STN, this represents the date that each compound was made accessible to the public. Per MPEP 2128, an electronic publication, including an online database or Internet publication (e.g., discussion group, forum, digital video, or social media post), is considered to be a "printed publication" within the meaning of 35 U.S.C. 102(a)(1) and pre-AIA 35 U.S.C. 102(a) and (b) provided the publication was accessible to persons concerned with the art to which the document relates. See In re Wyer, 655 F.2d 221, 227, 210 USPQ 790, 795 (CCPA 1981). . . Electronic publications on the internet or on an online database are considered to be publicly available as of the date the item was publicly posted.” Response to Arguments Applicant argues that the species relied upon in the previous Office Action’s prior art rejections have been deleted (see pgs. 6-7, Remarks). This argument is persuasive, expect for compound PNG media_image3.png 126 292 media_image3.png Greyscale . See the above prior art rejection over this compound for details. Free of the Prior Art Claim 14 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Claim 14 is free of the prior art. While STN Registry File 1837753-97-5 and STN Registry File 1580971-85-2, teach compounds of instant claim 13, these references do not teach these compounds in pharmaceutical compositions comprising a pharmaceutically acceptable carriers. Moreover, there is no motivation for an ordinary skilled artisan to add these compounds to pharmaceutical compositions comprising pharmaceutically acceptable carriers. As such, claim 14 is free of the prior art. Conclusion No claims are allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to LAUREN WELLS whose telephone number is (571)272-7316. The examiner can normally be reached M-F 7:00-4:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James (Jim) Alstrum-Acevedo can be reached on 571-272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /LAUREN WELLS/Examiner, Art Unit 1622
Read full office action

Prosecution Timeline

Nov 12, 2021
Application Filed
Jan 03, 2025
Non-Final Rejection — §102
Apr 15, 2025
Response Filed
Jun 10, 2025
Final Rejection — §102
Sep 11, 2025
Request for Continued Examination
Oct 03, 2025
Response after Non-Final Action
Nov 02, 2025
Non-Final Rejection — §102
Feb 04, 2026
Response Filed
Apr 05, 2026
Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599608
METHODS FOR TREATING CARDIAC VALVE DISEASE
2y 5m to grant Granted Apr 14, 2026
Patent 12576102
METHODS FOR IDENTIFYING PRE-DISPOSITION TO COGNITIVE DECLINE AND AGENTS FOR REDUCING OR PREVENTING COGNITIVE DECLINE, OR IMPROVING COGNITIVE ABILITY
2y 5m to grant Granted Mar 17, 2026
Patent 12559486
TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE
2y 5m to grant Granted Feb 24, 2026
Patent 12544357
COMPOSITIONS AND METHODS FOR THE TREATMENT OF PLASMODIUM FALCIPARUM MALARIA
2y 5m to grant Granted Feb 10, 2026
Patent 12539296
MONTELUKAST FOR THE TREATMENT OF EROSIVE HAND OSTEOARTHRITIS
2y 5m to grant Granted Feb 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

5-6
Expected OA Rounds
43%
Grant Probability
99%
With Interview (+57.8%)
2y 11m
Median Time to Grant
High
PTA Risk
Based on 213 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month